A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout

✍ Scribed by Reinders, M K; Haagsma, C; Jansen, T L T. A; van Roon, E N; Delsing, J; van de Laar, M A F J; Brouwers, J R B J

• Book ID: 118005431
• Publisher: BMJ Publishing Group
• Year: 2008
• Tongue: English
• Weight: 264 KB
• Volume: 68
• Category: Article
• ISSN: 0003-4967
• DOI: 10.1136/ard.2008.091462